Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 10, 2025, titled "Zydus launches biosimilar Denosumab 120 mg SC protecting bone health in cancer patients".
Press Release Dec 10 2025
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing the launch of a biosimilar product, Denosumab, aimed at protecting bone health in cancer patients. The biosimilar, named 'Zyrifa', is intended to reduce skeletal-related events in patients with various types of cancer. Dr. Sharvil P. Patel, the Managing Director, emphasized the importance of this medication in improving patient mobility and quality of life during cancer treatment.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Dec 09 2025
- Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada
- Press Release Dec 04 2025
- Press Release Nov 27 2025
- Press Release Nov 26 2025
Later from Zydus Lifesciences
- Press Release Dec 15 2025
- Zydus Lifesciences Limited Press Release Dec 19 2025
- Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®
- Press Release Dec 23 2025
- Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO(R), an Interchangeable Biosimilar to Lucentis(R)
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences